NMPA accepts supplemental Biologics License Application for enfortumab vedotin with Keytruda for treatment of bladder cancer

If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy

WuXi Biologics breaks ground on CRDMO Center in Singapore

The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network

Biocon to obtain approval for diabetes drug, Liraglutide in UK

Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus

lpca Laboratories enters into Technology Transfer Agreement with Omexa Formulary

Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market

Asahi Songwon Colors acquires remaining 22% stake in Atlas Life Sciences

Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%

Caplin Group commences operations of Rs. 150 crore oncology facility

The facility will manufacture tablets, capsules, and injections for the oncology segment

Warren Remedies commences commercial production of APIs

Akums introduces Hydroxyurea oral suspension for sickle cell disease

This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India

Merck invests € 300 million in new Life Science production site in South Korea

New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics

Lonza to buy US biologics site from Roche for US$ 1.2 billion

Lonza plans to invest approximately CHF 500 million to upgrade the facility